checkpoint inhibition in gi cancers: recent advances and their application in clinical practice
Published 3 years ago • 240 plays • Length 1:30:00Download video MP4
Download video MP3
Similar videos
-
1:31:24
checkpoint inhibition in gi cancers: recent advances in gastric, esophageal, and crc
-
59:11
immune checkpoint inhibitor therapy for locally advanced and early-stage esophageal/gej cancer
-
28:45
refining the role of immune checkpoint inhibitors in endometrial cancer
-
1:04:22
immunotherapy management of early and advanced gastric, esophageal, gej, and colorectal cancers
-
37:43
selective inhibition of oncogenic transcription and other approaches in the treatment of sclc
-
8:17
immune checkpoint inhibitors
-
44:56
immune checkpoint blockade in cancer therapy
-
3:01
treating patients with gastric cancer with immunotherapy: who will benefit?
-
21:57
therapeutic management of biliary cancers: integrating precision medicine with targeted strategies
-
59:06
gastric and gej cancers: treatment planning and sequencing in the era of immunotherapy
-
56:08
gaining confidence in predicting and assessing response to cancer immunotherapies
-
1:39:18
expanding the benefits of checkpoint inhibitors and targeted agents in triple-negative breast cancer
-
35:42
immunotherapy in crc | 2023 best of gi cancer conference
-
1:26:59
progress in immunotherapy biomarker testing and pathologic response assessment in solid tumors
-
33:06
maximizing the of potential current and emerging immunotherapies in advanced endometrial cancer
-
27:43
targeting the immune system with checkpoint inhibitors
-
1:05
limitations in immune checkpoint inhibitors in treating gastric cancer
-
0:55
enhancing the efficacy of immune checkpoint inhibitors in crc
-
55:16
targeting tigit to extend immunotherapy benefits to more cancer patients
-
59:58
management of esophageal/gej cancers: an interdisciplinary tumor board on adjuvant immunotherapy
-
5:06
safety and efficacy of immune checkpoint inhibitors in advanced penile squamous cell carcinoma
-
40:12
improving patient outcomes in urothelial carcinoma with novel antibody–drug conjugates